Cargando…

Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population

C-peptide measurement may represent a better index of pancreatic β-cell function compared to insulin. While insulin is mainly cleared by liver, C-peptide is mainly metabolized by kidneys. The aim of our study was to evaluate the association between baseline plasma C-peptide level and the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokooti, Sara, Kieneker, Lyanne M., de Borst, Martin H., Muller Kobold, Anneke, Kootstra-Ros, Jenny E., Gloerich, Jolein, van Gool, Alain J., Heerspink, Hiddo J. Lambers, T Gansevoort, Ron, Dullaart, Robin P.F., Bakker, Stephan J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564789/
https://www.ncbi.nlm.nih.gov/pubmed/32957570
http://dx.doi.org/10.3390/jcm9093001
_version_ 1783595794258984960
author Sokooti, Sara
Kieneker, Lyanne M.
de Borst, Martin H.
Muller Kobold, Anneke
Kootstra-Ros, Jenny E.
Gloerich, Jolein
van Gool, Alain J.
Heerspink, Hiddo J. Lambers
T Gansevoort, Ron
Dullaart, Robin P.F.
Bakker, Stephan J. L.
author_facet Sokooti, Sara
Kieneker, Lyanne M.
de Borst, Martin H.
Muller Kobold, Anneke
Kootstra-Ros, Jenny E.
Gloerich, Jolein
van Gool, Alain J.
Heerspink, Hiddo J. Lambers
T Gansevoort, Ron
Dullaart, Robin P.F.
Bakker, Stephan J. L.
author_sort Sokooti, Sara
collection PubMed
description C-peptide measurement may represent a better index of pancreatic β-cell function compared to insulin. While insulin is mainly cleared by liver, C-peptide is mainly metabolized by kidneys. The aim of our study was to evaluate the association between baseline plasma C-peptide level and the development of type 2 diabetes independent of glucose and insulin levels and to examine potential effect-modification by variables related to kidney function. We included 5176 subjects of the Prevention of Renal and Vascular End-Stage Disease study without type 2 diabetes at baseline. C-peptide was measured in plasma with an electrochemiluminescent immunoassay. Cox proportional hazards regression was used to evaluate the association between C-peptide level and type 2 diabetes development. Median C-peptide was 722 (566–935) pmol/L. During a median follow-up of 7.2 (6.0–7.7) years, 289 individuals developed type 2 diabetes. In multivariable-adjusted Cox regression models, we observed a significant positive association of C-peptide with the risk of type 2 diabetes independent of glucose and insulin levels (hazard ratio (HR): 2.35; 95% confidence interval (CI): 1.49–3.70). Moreover, we found significant effect modification by hypertension and albuminuria (p < 0.001 and p = 0.001 for interaction, respectively), with a stronger association in normotensive and normo-albuminuric subjects and absence of an association in subjects with hypertension or albuminuria. In this population-based cohort, elevated C-peptide levels are associated with an increased risk of type 2 diabetes independent of glucose, insulin levels, and clinical risk factors. Elevated C-peptide level was not independently associated with an increased risk of type 2 diabetes in individuals with hypertension or albuminuria.
format Online
Article
Text
id pubmed-7564789
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75647892020-10-26 Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population Sokooti, Sara Kieneker, Lyanne M. de Borst, Martin H. Muller Kobold, Anneke Kootstra-Ros, Jenny E. Gloerich, Jolein van Gool, Alain J. Heerspink, Hiddo J. Lambers T Gansevoort, Ron Dullaart, Robin P.F. Bakker, Stephan J. L. J Clin Med Article C-peptide measurement may represent a better index of pancreatic β-cell function compared to insulin. While insulin is mainly cleared by liver, C-peptide is mainly metabolized by kidneys. The aim of our study was to evaluate the association between baseline plasma C-peptide level and the development of type 2 diabetes independent of glucose and insulin levels and to examine potential effect-modification by variables related to kidney function. We included 5176 subjects of the Prevention of Renal and Vascular End-Stage Disease study without type 2 diabetes at baseline. C-peptide was measured in plasma with an electrochemiluminescent immunoassay. Cox proportional hazards regression was used to evaluate the association between C-peptide level and type 2 diabetes development. Median C-peptide was 722 (566–935) pmol/L. During a median follow-up of 7.2 (6.0–7.7) years, 289 individuals developed type 2 diabetes. In multivariable-adjusted Cox regression models, we observed a significant positive association of C-peptide with the risk of type 2 diabetes independent of glucose and insulin levels (hazard ratio (HR): 2.35; 95% confidence interval (CI): 1.49–3.70). Moreover, we found significant effect modification by hypertension and albuminuria (p < 0.001 and p = 0.001 for interaction, respectively), with a stronger association in normotensive and normo-albuminuric subjects and absence of an association in subjects with hypertension or albuminuria. In this population-based cohort, elevated C-peptide levels are associated with an increased risk of type 2 diabetes independent of glucose, insulin levels, and clinical risk factors. Elevated C-peptide level was not independently associated with an increased risk of type 2 diabetes in individuals with hypertension or albuminuria. MDPI 2020-09-17 /pmc/articles/PMC7564789/ /pubmed/32957570 http://dx.doi.org/10.3390/jcm9093001 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sokooti, Sara
Kieneker, Lyanne M.
de Borst, Martin H.
Muller Kobold, Anneke
Kootstra-Ros, Jenny E.
Gloerich, Jolein
van Gool, Alain J.
Heerspink, Hiddo J. Lambers
T Gansevoort, Ron
Dullaart, Robin P.F.
Bakker, Stephan J. L.
Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population
title Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population
title_full Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population
title_fullStr Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population
title_full_unstemmed Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population
title_short Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population
title_sort plasma c-peptide and risk of developing type 2 diabetes in the general population
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564789/
https://www.ncbi.nlm.nih.gov/pubmed/32957570
http://dx.doi.org/10.3390/jcm9093001
work_keys_str_mv AT sokootisara plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT kienekerlyannem plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT deborstmartinh plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT mullerkoboldanneke plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT kootstrarosjennye plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT gloerichjolein plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT vangoolalainj plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT heerspinkhiddojlambers plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT tgansevoortron plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT dullaartrobinpf plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation
AT bakkerstephanjl plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation